Mazen Hanna

Mazen Hanna

Auto-generated profile, based on publicly available information

Mazen Hanna

Cleveland Clinic, Cleveland, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in JACC
Verified
Journal Article
Closed access
BSBrett W. Sperry
Brett W. Sperry
BRBryan A. Reyes
Bryan A. Reyes
AIAsad Ikram
Asad Ikram
JDJoseph P. Donnelly
Joseph P. Donnelly
DPDermot Phelan
Dermot Phelan
MHMazen Hanna
Mazen Hanna

1 January 2017 in Cleveland Clinic Journal of Medicine
Verified
Journal Article
Closed access
JDJoseph P. Donnelly
Joseph P. Donnelly
MHMazen Hanna
Mazen Hanna
Cardiac amyloidosis (CA), once thought to be a rare disease, is increasingly recognized due to enhanced clinical awareness and better diagnostic imaging. CA is becoming of heightened interest to the cardiology community given more effective treatment strategies for light chain amyloidosis (AL), as well as emerging therapies for transthyretin amyloidosis (ATTR). Furthermore, reversing amyloid deposition in affected organs using monoclonal antibodies is actively being tested in clinical trials. A high index of suspicion and a systematic approach to the diagnosis of CA can lead to referral to a center of expertise for timely treatment.

1 March 2008 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
RWRaymond Ching-Chiew Wong
Raymond Ching-Chiew Wong
ZAZuheir Abrahams
Zuheir Abrahams
MHMazen Hanna
Mazen Hanna
JPJoseph Pangrace
Joseph Pangrace
GGGozalo Gonzalez-Stawinski
Gozalo Gonzalez-Stawinski
DTDavid Taylor
David Taylor

4 March 2025 in Circulation
Verified
Journal Article
Open access
DJDaniel Judge
Daniel Judge
JGJulian D. Gillmore
Julian D. Gillmore
KAKevin M. Alexander
Kevin M. Alexander
AAAmrut V. Ambardekar
Amrut V. Ambardekar
FCFrancesco Cappelli
Francesco Cappelli
MMMathew S. Maurer
Mathew S. Maurer
BACKGROUND: In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary end point. Participants with transthyretin amyloid cardiomyopathy who completed ATTRibute-CM were invited to enroll in an open-label extension study (OLE). We report the efficacy and safety data of acoramidis in participants who completed ATTRibute-CM and enrolled in the ongoing OLE. METHODS: Participants who previously received acoramidis through month 30 in ATTRibute-CM continued to receive it (continuous acoramidis), and those who received placebo through month 30 were switched to acoramidis (placebo to acoramidis). Participants who received concomitant tafamidis in ATTRibute-CM were required to discontinue it to be eligible to enroll in the OLE. Clinical efficacy outcomes analyzed through month 42 included time to event for all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH), ACM alone, first CVH alone, ACM or recurrent CVH, change from baseline in NT-proBNP (N-terminal pro-B-type natriuretic peptide), 6-minute walk distance, serum transthyretin, and Kansas City Cardiomyopathy Questionnaire Overall Summary score. Safety outcomes were analyzed through month 42. RESULTS: Overall, 438 of 632 participants in ATTRibute-CM completed treatment, and 389 enrolled in the ongoing OLE (263 continuous acoramidis and 126 placebo to acoramidis). The hazard ratio for ACM or first CVH was 0.57 (95% CI, 0.46–0.72) at month 42 based on a stratified Cox proportional hazards model ( P <0.0001) favoring continuous acoramidis. Similar analyses were performed on ACM alone and first CVH alone, with hazard ratios of 0.64 (95% CI, 0.47–0.88) and 0.53 (95% CI, 0.41–0.69), respectively, at month 42. Treatment effects for NT-proBNP and 6-minute walk distance also favored continuous acoramidis. On initiation of open-label acoramidis in the placebo-to-acoramidis arm, there was a prompt increase in serum transthyretin. Quality of life assessed by Kansas City Cardiomyopathy Questionnaire Overall Summary score was well preserved in continuous-acoramidis participants compared with the placebo-to-acoramidis participants. No new clinically important safety issues were identified in this long-term evaluation. CONCLUSIONS: Early initiation and continuous use of acoramidis in the ATTRibute-CM study through month 42 of the ongoing OLE study were associated with sustained clinical benefits in a contemporary transthyretin amyloid cardiomyopathy cohort, with no clinically important safety issues newly identified. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04988386.

12 April 2023 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
EAEmmanuel Akintoye
Emmanuel Akintoye
MMMuhammad Majid
Muhammad Majid
AKAllan L. Klein
Allan L. Klein
MHMazen Hanna
Mazen Hanna

25 January 2014 in Current Heart Failure Reports
Verified
Journal Article
Closed access
PDF file
MHMazen Hanna
Mazen Hanna